Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

v3.24.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 9 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Cash flows from operating activities:    
Net loss $ (1,012,938) $ (4,189,655)
Adjustments to reconcile net loss to net cash used in operating activities:    
Other non-cash expense 0 165,868
Stock issued for services 0 2,278
Stock issued for compensation 0 7,334
Stock-based compensation 674,693 638,072
Change in fair value of warrant liability (2,633,000) 0
Change in fair value of derivative liability 663,000 0
Change in fair value of convertible note receivable (138,000) 0
Change in fair value of warrant asset 416,000 0
Change in assets and liabilities:    
Increase in prepaid expenses and other current assets (190,081) (86,836)
Increase in accounts payable 355,918 74,706
Increase (decrease) in accrued expenses 45,909 (117,110)
Net cash used in operating activities (1,818,499) (3,505,343)
Cash flows from investing activities:    
Investment - note receivable and warrants (5,000,000) 0
Net cash used in investing activities (5,000,000) 0
Cash flows from financing activities:    
Repurchase of common stock (27,022,987) (9,254,005)
Proceeds from issuance of preferred stock, net of transaction costs 33,650,075 0
Redemption of preferred stock (6,638,197) 0
Proceeds from warrant exercise 70 880
Net cash used in financing activities (11,039) (9,253,125)
Effect of currency rate exchange on cash and cash equivalents (70) (1,970)
Net decrease in cash and cash equivalents (6,829,608) (12,760,438)
Cash and cash equivalents at beginning of the periods 68,039,936 85,400,656
Cash and cash equivalents at end of the periods 61,210,328 72,640,218
Supplemental disclosure of cash flows information:    
Cash paid during the periods for income taxes 1,600 0
Supplemental schedule of non-cash investing and financing activities:    
Non-cash derivative liability at initial fair value 2,770,000 0
Non-cash warrant liability at initial fair value 14,127,000 0
Reclassification of Series B Convertible Preferred Stock and dividends to current liability 12,918,299 0
Accretion of discounts to redemption value of Series B Preferred Stock 11,995,681 0
Excise tax accrued on repurchase of common stock $ 270,230 $ 0